Risk of abnormally slow heart rate twice as high in those taking drugs to slow Alzheimer's

Oct 01, 2009

People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications.

Researchers from St. Michael's Hospital and Ontario's Institute for Clinical Evaluative Sciences (ICES) analyzed data from 1.4 million people aged 67 and older to see whether the risk for bradycardia was higher for those taking drugs called cholinesterase inhibitors.

Bradycardia is defined as an abnormally slow resting heart rate (under 60 beats per minute). Although it can be asymptomatic, it can also cause fainting, palpitations, shortness of breath, or even death.

"We wanted to see if there was a link between initiation of a cholinesterase inhibitor and subsequent hospitalization for bradycardia," explains lead author Laura Y. Park-Wyllie, a researcher at St. Michael's Hospital .

The three cholinesterase-inhibiting drugs currently approved for use in Canada are donepezil (brand name Aricept); rivastigmine (marketed as Exelon and Exelon Patch); and galantamine (branded Reminyl).

Most of the patients whose records were analyzed for the study had been prescribed donepezil.

The results of the study showed that older patients hospitalized with bradycardia were more than twice as likely to have recently started on a cholinesterase inhibitor such as donepezil for Alzheimer's disease compared to those without bradycardia.

The findings appear in the September 2009 issue of PLoS Medicine, an open-access online medical journal.

The researchers say that as the prevalence of Alzheimer's disease and other forms of dementia increases, more people aged 65 years and older will be treated with a cholinesterase inhibitor.

"It will be increasingly more important to prescribe these drugs judiciously as they carry a risk of serious adverse events," Park-Wyllie says. "A careful clinical evaluation is required before and after initiating these drugs, and they should only be continued when there is a definite positive response."

The potential cardiovascular toxicity of these dementia drugs may be underappreciated by clinicians, Park-Wyllie adds. More than half of the patients who had been hospitalized with bradycardia resumed taking their cholinesterase inhibitor after being discharged.

"Our study provides evidence of the potential adverse effect of cholinesterase inhibitors on heart rate. Health professionals need to reassess the merits of continued therapy in patients who develop bradycardia while taking these drugs," she says.

About cholinesterase inhibitors and dementia

Cholinesterase inhibitors are commonly prescribed to delay the progression of symptoms such as confusion and long-term memory loss in people with mild to moderate Alzheimer's disease.

It's known that people with dementia tend to have lower levels of a brain chemical called acetylcholine; the drugs work by boosting these levels.
Reported side effects—including diarrhea, muscle cramps and abnormally slow heartbeat—may be related to increasing levels of acetylcholine in the body.

The benefits of cholinesterase inhibitors for people with Alzheimer's disease are generally small. The drugs do not reverse the effects of dementia. Other research suggests that in about half of patients, the drugs delay the worsening of symptoms for between six months to a year, although a minority of patients may benefit more.

Related Stories

Researchers have examined the evidence in favour of giving people considered to be close to developing dementia the drugs that are most commonly used to treat the condition itself. They have concluded that these drugs (cholinesterase ...

Cholinesterase inhibitors, used to treat cognitive symptoms of Alzheimer's disease, are also a safe and effective alternative therapy for the behavioral and psychological symptoms of dementia, according to a study that appears ...

People with Alzheimer's disease who take vitamin E appear to live longer than those who don't take vitamin E, according to research that will be presented at the American Academy of Neurology 60th Anniversary Annual Meeting ...

Extended treatment with Alzheimer's disease drugs can significantly slow the rate at which the disorder advances, and combination therapy with two different classes of drugs is even better at helping patients maintain their ...

Older nursing home residents who took medications for dementia and incontinence at the same time had a 50 percent faster decline in function than those who were being treated only for dementia, according to a study from researchers ...

ZMapp, the experimental Ebola drug that won notoriety when it was given to a handful of infected aid workers at the height of the epidemic, will now begin clinical testing in Liberian treatment centers, U.S. health authorities ...

Public health experts can identify nations that are vulnerable to the occurrence and impact of future outbreaks of Ebola or other emergencies by using a screening tool that evaluates a nation's strengths across a wide range ...

Vienna's public lavatories were at the focus of a study by the Global Food Safety research group at the Vetmeduni Vienna. The researchers studied 224 public restrooms in Vienna, which are about 91 percent ...

Known for years as the "career woman's disease" based on the idea that women without children develop disease in their reproductive organs, endometriosis is a painful condition thought to affect one in ten wome ...

User comments : 0

Please sign in to add a comment.
Registration is free, and takes less than a minute.
Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.

Javascript is currently disabled in your web browser. For full site functionality, it is necessary to enable Javascript.
In order to enable it, please see these instructions.